, 12:P194
Date: 13 Mar 2008

Early elevation of plasma soluble CD14 subtype, a novel biomarker for sepsis, in a rabbit cecal ligation and puncture model

This is an excerpt from the content

Introduction

To reduce the mortality rates of patients with sepsis, rapid diagnosis and therapeutic decision are required. We have therefore discovered the soluble CD14 subtype (sCD14-ST), which is specific for sepsis and is elevated at an early stage during the disease progression [1]. Additionally, we have been researching a novel fusion protein, MR1007, which consists of the modified light chain of interalpha inhibitor and the anti-CD14 antibody as an anti-sepsis agent.

Methods

We developed an ELISA using two rat monoclonal antibodies against N-terminal and C-terminal peptide sequences of rabbit sCD14-ST, respectively, to determine sCD14-ST concentrations in rabbit plasma. Survival rates and the time course of plasma levels of sCD14-ST, IL-6, and D-dimer were examined in a rabbit cecal ligation and puncture (CLP) model. Blood bacterial counts were also determined as colony-forming units.

Results

The plasma sCD14-ST levels in seven dead animals clearly increased at 2 hours or later togeth